This page is part of the FHIR Specification (v1.2.0: STU 3 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions
This is the narrative for the resource. See also the XML or JSON format.
AC followed by Paclitaxel + Trastuzumab Course 1
Name: Cyclophosphamide in AC (Doxorubicin + Cyclophosphamide)
Course: 1
Agent Protocols Options:
Cyclophosphamide 600 mg/m^2 IV over 30 minutes D1
Offset: None
Cycle length: Q21D x 4 cycles
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.